Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

D Porter¹, N Frey², P A Wood³, Y Weng³, S A Grupp^{4

5}

Affiliations

¹ Division of Hematology-Oncology, Blood and Marrow Transplantation and Cellular Therapy Program, Perelman School of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. David.Porter@uphs.upenn.edu.
² Division of Hematology-Oncology, Blood and Marrow Transplantation and Cellular Therapy Program, Perelman School of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
³ Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁴ Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA.
⁵ Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, 3501 Civic Center Blvd. CTRB 3006, Philadelphia, PA, 19104, USA.

Published Erratum

D Porter et al. J Hematol Oncol. 2018.

. 2018 Jun 13;11(1):81.

doi: 10.1186/s13045-018-0627-z.

D Porter¹, N Frey², P A Wood³, Y Weng³, S A Grupp^{4

5}

¹ Division of Hematology-Oncology, Blood and Marrow Transplantation and Cellular Therapy Program, Perelman School of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. David.Porter@uphs.upenn.edu.
² Division of Hematology-Oncology, Blood and Marrow Transplantation and Cellular Therapy Program, Perelman School of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
³ Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁴ Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA.
⁵ Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, 3501 Civic Center Blvd. CTRB 3006, Philadelphia, PA, 19104, USA.

Abstract

The original article contains several small errors. The errors & concurrent corrections are listed below [1].

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.
Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Porter D, et al. J Hematol Oncol. 2018 Mar 2;11(1):35. doi: 10.1186/s13045-018-0571-y. J Hematol Oncol. 2018. PMID: 29499750 Free PMC article. Review.

1. Porter D, et al. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11:35. doi: 10.1186/s13045-018-0571-y. - DOI - PMC - PubMed
1. Proceedings of the Haematologica: Ferrata Storti Foundation via Giuseppe Belli 4, 27100 Pavia, Italy; 2017.
1. Patel YB, Kantarjian HM, Thomas D, O’Brien S, Ravandi F, Garcia-Manero G, Cortes J, Konopleva M, Jain N, Garris R, Autry J, Jabbour EJ. Characterization of fever, infection, and cytokine release syndrome (CRS) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia treated with blinatumomab [abstract]. Blood. 2015;125(abstract 2530)
1. Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D, investigators VASST. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358:877–887. doi: 10.1056/NEJMoa067373. - DOI - PubMed